Mounjaro medicine: what it is, how it works and what to expect

Step 1: understanding what tirzepatide medicine actually does

Most people expect an injectable weight-loss medicine to work like a diet pill — something that suppresses hunger through willpower chemistry. Tirzepatide does something more structural than that. It mimics two hormones your gut releases after eating: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Activating both receptors at once slows how quickly food leaves your stomach, signals fullness to your brain sooner, and helps regulate blood sugar. The result is that many people find themselves physically less hungry rather than simply trying harder to eat less.

You can read the NHS's patient-level overview of tirzepatide on the NHS medicines pages, which explains the mechanism in plain language and lists what the medicine is used for. It is also worth knowing that Mounjaro holds a UK licence specifically for weight management, this distinguishes it from some other GLP-1 medicines whose primary licensed use is type 2 diabetes. More on the broader category is covered in our guide to tirzepatide medicines in the UK.

The pen itself is a pre-filled KwikPen delivering one injection per week, subcutaneously into the abdomen, thigh, or upper arm. Rotating injection sites is recommended. Storage is in a refrigerator at 2–8°C; the patient information leaflet gives the exact window for keeping it at room temperature if needed, and that is the document to follow on that detail.

Step 2: what the dose schedule looks like (and why the first pen is not the full picture

A common misconception is that the starter dose) 2.5 mg, is the dose doing the work. It is not, and people sometimes feel discouraged when week three brings modest changes. The first pen's entire job is settling your system: nausea, indigestion and fatigue are far easier to manage when the dose climbs slowly. The prescriber typically increases in 4-week steps through 5, 7.5, 10, 12.5 and 15 mg, stopping at the highest dose you tolerate well.

What this means in practice: most people do not reach their maintenance dose until several months in. If you are curious about what early treatment actually feels like, the experience around week three on Mounjaro is one of the questions our prescribers hear most often, and the short answer is that it is still very early days. The SURMOUNT-1 trial, published in the New England Journal of Medicine and involving 2,539 adults over 72 weeks, found average body-weight reductions of around 20–21% at 15 mg, but that reflects the full treatment period, not the first few weeks at a starter dose.

UK available strengths are 2.5, 5, 7.5, 10, 12.5 and 15 mg. No dose should be changed without a prescriber's input; your clinical review is the right place to raise any concerns about tolerability or progress.

Step 3: knowing the side-effect profile before you start

The side effects most associated with Mounjaro are gastrointestinal. Nausea is the most reported, followed by diarrhoea, constipation, vomiting, indigestion and burping. These tend to peak after starting or after a dose increase, and for many people they settle within a week or two. Headache, fatigue and dizziness are also reported. Injection-site reactions are generally mild.

There are rarer but more serious effects to be aware of. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines: severe stomach pain that spreads to the back, with or without vomiting, needs urgent medical attention. Gallbladder problems, severe allergic reactions and signs of dehydration from persistent vomiting or diarrhoea also warrant prompt clinical contact. You can report any suspected side effect directly to the MHRA through the Yellow Card scheme.

Mounjaro is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma or MEN2 should not use it. The complete contraindications list is in the patient information leaflet that comes with every pen. If you are on other medication, our page covering what medicines you cannot take with Mounjaro covers the main interactions in detail, and is a useful starting point before your consultation.

Step 4: who can access it and what the private route involves

On the NHS, tirzepatide access is phased and currently limited to people meeting strict BMI and comorbidity thresholds, NICE's appraisal TA1026 sets out the eligibility criteria in full, and uptake through GP practices began from April 2026, with eligibility expanding in stages. Many people do not meet the current NHS criteria or prefer not to join a waiting list.

The private route requires the same clinical rigour: a prescription from a qualified independent prescriber, following a proper consultation. There are no shortcuts, anyone selling these pens without a clinical assessment in place is operating outside the law, and the MHRA has seized large volumes of counterfeit pens from illegal online sellers. Checking any pharmacy on the GPhC register before ordering is a straightforward way to confirm it is legitimate. If you take medication for hypertension, our guidance on taking tirzepatide alongside blood pressure medicine is worth reading before you begin, and our page on what medicine you should not take with Mounjaro is a helpful broader reference if you are managing multiple medications.

For context on what private treatment typically costs in the UK, our page on the Eli Lilly Mounjaro price increase explains how list prices changed from September 2025 and what that means for private patients. If you would like to explore whether Mounjaro could be right for you, start your free consultation and a GPhC-registered prescriber will review your answers the same day.